A recurring error across round-ups, and the likely origin of several of the wrong figures we corrected.
Many programs advertise a discounted first month — $99, $149, $199 — that reverts to a materially higher ongoing rate. Round-ups repeatedly publish the promotional figure as the standing price.
Sprout Health is a clean example: widely listed at $199, its own site states $299, with $199 appearing as a first-month promotion. Embody's $99 and $119 figures behaved the same way against a checkout rate reported at $349.
The effect compounds with dose-scaling. A promotional entry price at a program that also reprices with dose can understate a twelve-month total by more than a thousand dollars.
Ask whether the quoted rate holds at renewal, and get it in writing. That single answer moves the annual figure more than any other question you can ask.
Sources
- Provider published pricing pages and named third-party reviews, 2026
Dated 2026-04-10. If this item is out of date or wrong, tell us through contact and the change is logged in corrections.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.